Real world data (RWD) from the AIO ColoPredict Plus (CPP) registry (AIO-KRK-0413/ass): Impact of the Sars-CoV-2 pandemic on enrollment of patients (pts.) with colorectal cancer (CRC) -analysis for the CancerCOVID consortium

ABSTRACT

Purpose: CRC prognosis has improved through guideline-based care. COVID-19 pandemic lead to re-allocation of health care resources potentially putting sections of cancer care at a disadvantage. We compared enrollment and clinical subgroups into our registry before and during the first (fw) and second wave (sw) of the COVID-19 pandemic. Method(s) CPP assembles clinical, histo-pathological and molecular data of pts. with resected CRC. Prospectively enrolled pts. during the fw (4-6/2020) and the sw (10-12/2020) were analyzed, focusing on total numbers, age and sex compared to corresponding pre-pandemic intervals of 2019. Due to site expansion (70 to 161) of CPP we calculated quarterly counts per site and in relation to total enrollment. Result(s) 2221 pts. enrolled into CPP during 2019 and 2020 were included, 47 % female (F) /53 % male (M). Mean age in 2019 was 71.9 years (y) vs 71.6 y in 2020. Mean number of pts. enrolled in CPP with primary diagnosis of CRC per site 2019/2020 fw 8,5/6.9 and sw 6.2/5.8. Evaluation for age showed 2019%/2020% fw >70 y was 52.5/53.5 and <=70 y 47.5/ 46.5 respectively;for the sw > 70 y was 45.6/ 53.5;<=70 y 54.4/46.5. M vs F in fw 2019%/2020% M 50.5/61;F 49.5/39;in sw M 57.6/56;F 42.4/44. Discussion(s) CPP did not detect substantial differences in total counts of enrolled patients or distribution of age and sex. We detected a slight dip in enrollment together with a small shift toward men in fw as well as to elderly pts. in sw. Enrollment of pts. into registries seems to be feasible even in pandemic situation. Potentially, a possible data bias as preference of registry enrollment over randomized controlled trials. Conclusion(s) Real world data from CPP must be complemented by additional data for comprehensive assessment of colon cancer care and will be complemented for final data presentation in 2022 with data collected during the third and omicron wave.